Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Kerr

Showing results (721-730 of 822) with videos related to

Pageof 83
Sort By:
Chest|July 29, 1999
Use of genetically altered mice to investigate the role of nuclear factor-kappa B activation and cytokine gene expression in sepsis-induced ARDST S Blackwell, F E Yull, C L Chen, et al.
Journal of Psychosocial Oncology|December 28, 2024
Feasibility of implementing a culturally and linguistically adapted telephone-based cognitive-behavioral therapy (CBT) intervention for depression and anxiety with Hispanic and Latino cancer survivorsSuzanne C Danhauer, Janet A Tooze, Tebianne Abubaker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 2, 1998
Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: selection of a biologically active and tolerable dose for longer-term studiesJ Nemunaitis, C Poole, J Primrose, et al.
American Journal of Respiratory and Critical Care Medicine|September 16, 2000
Multiorgan nuclear factor kappa B activation in a transgenic mouse model of systemic inflammationT S Blackwell, F E Yull, C L Chen, et al.
Gut|February 14, 1998
One week triple therapy for Helicobacter pylori: a multicentre comparative study. Lansoprazole Helicobacter Study GroupJ J Misiewicz, A W Harris, K D Bardhan, et al.
Alimentary Pharmacology & Therapeutics|September 3, 1998
Incidence of duodenal ulcer healing after 1 week of proton pump inhibitor triple therapy for eradication of Helicobacter pylori. The Lansoprazole Helicobacter Study GroupA W Harris, J J Misiewicz, K D Bardhan, et al.
Alimentary Pharmacology & Therapeutics|January 9, 1999
Maintenance of remission of ulcerative colitis: a comparison between balsalazide 3 g daily and mesalazine 1.2 g daily over 12 months. ABACUS Investigator groupJ R Green, J A Gibson, G D Kerr, et al.
The Journal of Emergency Medicine|May 29, 2012
Workplace violence in emergency medicine: current knowledge and future directionsTerry Kowalenko, Rebecca Cunningham, Carolyn J Sachs, et al.
Oncology Reports|May 11, 2006
Structure-activity studies with cytotoxic anthrapyrazolesAsher Begleiter, Denny Lin, Kimberly K Larson, et al.
Gastroenterology|January 15, 1998
Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis. The Abacus Investigator GroupJ R Green, A J Lobo, C D Holdsworth, et al.
Pageof 83

Showing results (721-730 of 822) with videos related to

Sort By:
Pageof 83
Chest|July 29, 1999
Use of genetically altered mice to investigate the role of nuclear factor-kappa B activation and cytokine gene expression in sepsis-induced ARDST S Blackwell, F E Yull, C L Chen, et al.
Journal of Psychosocial Oncology|December 28, 2024
Feasibility of implementing a culturally and linguistically adapted telephone-based cognitive-behavioral therapy (CBT) intervention for depression and anxiety with Hispanic and Latino cancer survivorsSuzanne C Danhauer, Janet A Tooze, Tebianne Abubaker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 2, 1998
Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: selection of a biologically active and tolerable dose for longer-term studiesJ Nemunaitis, C Poole, J Primrose, et al.
American Journal of Respiratory and Critical Care Medicine|September 16, 2000
Multiorgan nuclear factor kappa B activation in a transgenic mouse model of systemic inflammationT S Blackwell, F E Yull, C L Chen, et al.
Gut|February 14, 1998
One week triple therapy for Helicobacter pylori: a multicentre comparative study. Lansoprazole Helicobacter Study GroupJ J Misiewicz, A W Harris, K D Bardhan, et al.
Alimentary Pharmacology & Therapeutics|September 3, 1998
Incidence of duodenal ulcer healing after 1 week of proton pump inhibitor triple therapy for eradication of Helicobacter pylori. The Lansoprazole Helicobacter Study GroupA W Harris, J J Misiewicz, K D Bardhan, et al.
Alimentary Pharmacology & Therapeutics|January 9, 1999
Maintenance of remission of ulcerative colitis: a comparison between balsalazide 3 g daily and mesalazine 1.2 g daily over 12 months. ABACUS Investigator groupJ R Green, J A Gibson, G D Kerr, et al.
The Journal of Emergency Medicine|May 29, 2012
Workplace violence in emergency medicine: current knowledge and future directionsTerry Kowalenko, Rebecca Cunningham, Carolyn J Sachs, et al.
Oncology Reports|May 11, 2006
Structure-activity studies with cytotoxic anthrapyrazolesAsher Begleiter, Denny Lin, Kimberly K Larson, et al.
Gastroenterology|January 15, 1998
Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis. The Abacus Investigator GroupJ R Green, A J Lobo, C D Holdsworth, et al.
Pageof 83